t-cell-therapy
(7)
Triumvira Immunologics, Inc.
Triumvira Immunologics is a clinical-stage immuno-oncology company developing engineered T cell therapies built on its proprietary T cell Antigen Coupler (TAC) platform. Unlike CAR-T, the TAC molecule co-opts the natural T cell receptor to recognize and attack cancer cells, aiming for a more physiological immune response with a potentially safer profile. The company advances autologous and allogeneic TAC T cell candidates against solid-tumor antigens such as HER2, Claudin 18.2, GPC3 and GUCY2C.
Eureka Therapeutics, Inc.
Eureka Therapeutics is a clinical-stage biopharmaceutical company in Emeryville, California, developing next-generation T-cell therapies for cancer, with a focus on hard-to-treat solid tumors. Founded in 2006 by Dr. Cheng Liu, the company pairs its E-ALPHA phage-display antibody engine with its ARTEMIS T-cell receptor platform - an alternative to conventional CAR-T designed to keep engineered T cells potent inside immunosuppressive tumors while sharply reducing the inflammatory cytokine release linked to CAR-T toxicity. Its lead program, ECT204, targets GPC3-positive advanced liver cancer and has received FDA RMAT designation.
T-knife Therapeutics
T-knife Therapeutics is a clinical-stage biotech engineering T-cell receptor (TCR-T) therapies to treat solid tumors. Spun out of Berlin's Max Delbrück Center in 2015, it built a proprietary humanized-TCR mouse platform (HuTCR) that grows a full human immune repertoire in mice, letting the company harvest fully human TCRs naturally selected for affinity and specificity. Now dual-based in San Francisco and Berlin, T-knife is advancing 'supercharged' TCR-T candidates - including a PRAME-targeted, CRISPR-armored therapy (TK-6302) entering the clinic - against cancers that have long resisted cell therapy.
Alla Zamarayeva
Alla Zamarayeva is the co-founder and CEO of CellFE, a Bay Area biotech building a non-viral, microfluidics-based platform for engineering human cells. A UC Berkeley engineering PhD and former Goldwater Scholar, she spun a piece of academic research she stumbled onto during her doctorate into a company aiming to make cell therapies cheaper, gentler, and eventually available at the point of care. In 2023 she led CellFE to a $22 million Series A backed by M Ventures, and she is steering the company toward redefining how gene-edited cell therapies are manufactured.
BlueSphere Bio
BlueSphere Bio is a Pittsburgh-based clinical-stage biotechnology company developing personalized T-cell receptor (TCR) therapies for cancer. Spun out of the University of Pittsburgh and UPMC Enterprises in 2017, the company's proprietary TCXpress platform rapidly discovers and screens natural T-cell receptors that can target cancer antigens hidden inside cells - a reach beyond what conventional CAR-T therapies achieve. Its lead programs target high-risk hematologic malignancies such as relapsed/refractory acute myeloid leukemia.
Kim Jaffe
Kim Jaffe, PhD, is Chief Business Officer at BlueSphere Bio, a Pittsburgh-based clinical-stage biotech building personalized T-cell receptor therapies for cancer using its TCXpress discovery platform. A bench scientist turned dealmaker, she trained in cell and molecular biology at Northwestern and Princeton, ran cell-line development and R&D at clinical-stage oncology companies, and now leads strategy, partnerships, and business development as the company pushes TCR T-cell candidates toward high-risk leukemias.
Cheng Liu
Cheng Liu is the founder, President, and CEO of Eureka Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Emeryville, California. A molecular cell biologist trained at UC Berkeley and Peking University, Liu invented a novel class of TCR mimic antibodies that allow engineered T cells to recognize intracellular tumor antigens - a major challenge in treating solid tumors. Since founding Eureka in 2006 after a decade at Chiron/Novartis, he has built a pipeline of ARTEMIS T-cell therapies targeting liver cancer, multiple myeloma, and neuroblastoma, with the company's ECT204 program earning FDA RMAT Designation in January 2026 - one of the highest-priority designations the FDA gives to regenerative medicine therapies. Eureka has raised over $168 million in total funding and holds more than 500 patents worldwide.